entinostat has been researched along with Dermatitis, Eczematous in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the role of topical Entinostat, a selective inhibitor of histone deacetylases 1 (HDAC1) that has been tested in clinic trials to treat solid tumors and hematological malignancies, in psoriasis therapy." | 4.31 | Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response. ( Jiang, Y; Lai, Y; Lu, S; Wang, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y | 1 |
| Lu, S | 1 |
| Lai, Y | 1 |
| Wang, L | 1 |
1 other study available for entinostat and Dermatitis, Eczematous
| Article | Year |
|---|---|
Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response.
Topics: Animals; Disease Models, Animal; Eczema; Histone Deacetylase 1; Humans; Imiquimod; Interleukin-17; M | 2023 |